主要文件

查看所有文档

M9766

4-甲基伞形酮 α- D -吡喃葡萄糖苷

Name: 4-甲基伞形酮 &#945;-<SC> D </SC>-吡喃葡萄糖苷
Brand: SIGMA

α-glucosidase substrate, fluorogenic, ≥99% (TLC), powder

别名:

4-甲基伞形酮 α- D -葡萄糖苷

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₆H₁₈O₈

化学文摘社编号:

17833-43-1

分子量:

338.31

NACRES:

NA.32

PubChem Substance ID:

24897365

UNSPSC Code:

12352204

EC Number:

241-794-0

MDL number:

MFCD00067661

Beilstein/REAXYS Number:

1690776

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

4-甲基伞形酮 α- D -吡喃葡萄糖苷, α-glucosidase substrate

Quality Level

300

assay

≥99% (TLC)

form

powder

solubility

pyridine: 50 mg/mL, clear, colorless to faintly yellow

storage temp.

−20°C

SMILES string

CC1=CC(=O)Oc2cc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc12

InChI

1S/C16H18O8/c1-7-4-12(18)23-10-5-8(2-3-9(7)10)22-16-15(21)14(20)13(19)11(6-17)24-16/h2-5,11,13-17,19-21H,6H2,1H3/t11-,13-,14+,15-,16+/m1/s1

InChI key

YUDPTGPSBJVHCN-JZYAIQKZSA-N

说明

Application

4-甲基伞形基ǥ-D-吡喃葡糖苷已用于测定组织匀浆中的酸性 α-葡萄糖苷酶（GAA）活性。

Biochem/physiol Actions

4-甲基伞形基ǥ-D-吡喃葡糖苷是 ǥ-葡萄糖苷酶的荧光底物。产物 4-甲基伞形花酯在荧光光谱中显示出 440nm 处的峰值。

Still not finding the right product?

Explore all of our products under 4-甲基伞形酮 α- D -吡喃葡萄糖苷

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Probiotics and Human Health

Probiotics exhibit an inhibitory effect on pathogens, help prevent chronic intestinal inflammatory diseases or atopic syndromes, and support the immune system.

A new resorufin-based alpha-glucosidase assay for high-throughput screening.

Omid Motabar et al.

Analytical biochemistry, 390(1), 79-84 (2009-04-18)

Mutations in alpha-glucosidase cause accumulation of glycogen in lysosomes, resulting in Pompe disease, a lysosomal storage disorder. Small molecule chaperones that bind to enzyme proteins and correct the misfolding and mistrafficking of mutant proteins have emerged as a new therapeutic

Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.

Darin J Falk et al.

Molecular therapy : the journal of the American Society of Gene Therapy, 21(9), 1661-1667 (2013-06-05)

Pompe disease is a neuromuscular disease resulting from deficiency in acid α-glucosidase (GAA), results in cardiac, skeletal muscle, and central nervous system (CNS) pathology. Enzyme replacement therapy (ERT) has been shown to partially correct cardiac and skeletal muscle dysfunction. However

Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Phillip A Doerfler et al.

Human gene therapy, 27(1), 43-59 (2015-11-26)

Pompe disease is a progressive neuromuscular disorder caused by lysosomal accumulation of glycogen from a deficiency in acid alpha-glucosidase (GAA). Replacement of the missing enzyme is available by repeated protein infusions; however, efficacy is limited by immune response and inability

查看所有相关文献

全球贸易项目编号

货号	GTIN
M9766-10MG	04061834064565
M9766-25MG	04061835557783
M9766-100MG	04061834064558
M9766-250MG	04061835546190
M9766-1G	04061835557776